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Background: Significant paravalvular leak (PVL) after transcatheter aortic valve replacement (TAVR) confers a worse
prognosis. Symptoms related to significant PVL may be difficult to differentiate from those related to other causes
of heart failure. Cardiovascular magnetic resonance (CMR) directly quantifies valvular regurgitation, but has not been
extensively studied in symptomatic post-TAVR patients.
Methods: CMR was compared to qualitative (QE) and semi-quantitative echocardiography (SQE) for classifying PVL
and prognostic value at one year post-imaging in 23 symptomatic post-TAVR patients. The primary outcome was a
composite of all-cause death, heart failure hospitalization, and intractable symptoms necessitating repeat invasive
therapy; the secondary outcome was a composite of all-cause death and heart failure hospitalization. The difference
in event-free survival according to greater than mild PVL versus mild or less PVL by QE, SQE, and CMR were evaluated
by Kaplan-Meier survival analysis.
Results: Compared to QE, CMR reclassified PVL severity in 48% of patients, with most patients (31%) reclassified to
at least one grade higher. Compared to SQE, CMR reclassified PVL severity in 57% of patients, all being reclassified to
at least one grade lower; SQE overestimated PVL severity (mean grade 2.5 versus 1.7, p = 0.001). The primary and
secondary outcomes occurred in 48% and 35% of patients, respectively. Greater than mild PVL by CMR was associated
with reduced event-free survival for the primary outcome (p < 0.0001), however greater than mild PVL by QE and SQE
were not (p = 0.83 and p = 0.068). Greater than mild PVL by CMR was associated with reduced event-free survival for
the secondary outcome, as well (p = 0.012).
Conclusion: In symptomatic post-TAVR patients, CMR commonly reclassifies PVL grade compared with QE and SQE.
CMR provides superior prognostic value compared to QE and SQE, as patients with greater than mild PVL by CMR
(RF > 20%) had a higher incidence of adverse events.
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Transcatheter aortic valve replacement (TAVR) has trans-
formed the contemporary management of patients with
severe aortic stenosis and high surgical risk [1,2]. Despite
extensive pre-procedure evaluation, greater than mild
paravalvular leak (PVL) occurs in over 10% of patients
undergoing TAVR and is associated with worse short and
long term outcomes [3,4]. Echocardiography, the standard
non-invasive method of imaging PVL, often has limited
utility due to multiple eccentric regurgitant jets [5]. Acous-
tic shadowing from the valve stent and native aortic valve
calcification may further complicate the estimation of PVL.
The Valve Academic Research Consortium II (VARC II)
has proposed a semi-quantitative method of PVL classifica-
tion by the extent of circumferential involvement relative
to the prosthetic valve stent on two-dimensional echocar-
diography [6], which is yet to be validated.
Accurate identification of post-TAVR PVL by cardiac
imaging is essential, as symptoms from PVL may be dif-
ficult to clinically differentiate from symptoms related
to other common causes of heart failure, such as sys-
tolic and diastolic dysfunction. Cardiovascular magnetic
resonance (CMR) flow assessment provides accurate
and reproducible quantification of valvular regurgita-
tion [7,8]. The direct measurement of forward and re-
verse flow volumes by CMR facilitates the calculation
of the aortic regurgitant fraction (RF) for severity classi-
fication. Small studies have demonstrated the feasibility
of CMR for evaluation of post-TAVR PVL [9-11], how-
ever, these studies did not address diagnostic and prog-
nostic value in symptomatic patients. The purpose of
our study was to evaluate CMR in post-TAVR patients
in whom there was concern for clinically significant
PVL. In addition to PVL classification, we assessed the
ability of CMR findings to predict outcomes at one year
post-imaging.Figure 1 Semi-quantitative echocardiographic (SQE) measurement
of paravalvular leak (PVL) using circumferential extent of PVL
in the parasternal short-axis by the Valve Academic Research
Consortium II method. The green circle represents the circumference
of the paravalvular leak. The purple circle represents the circumference
of the transcatheter valve stent frame. The circumferential extent is the
sum of the paravalvular leak jet circumference(s) divided by the valve
circumference (mild <10%, moderate 10-30%, severe >30%).Methods
Study population
The study was approved and performed in accordance
with the regulations of the university’s institutional re-
view board (Emory University Hospital, Atlanta, Georgia).
We retrospectively reviewed all patients at our center
from 2009 to 2013 that underwent CMR post-TAVR.
Patients had been implanted with either a balloon-
expandable or self-expanding transcatheter aortic pros-
thesis. We included all patients undergoing CMR for
evaluation of heart failure symptoms persisting or recur-
ring after TAVR, which were potentially related to PVL
seen on transthoracic echocardiography (TTE). A detailed
medical history, laboratory values and TTE findings were
collected to establish baseline demographics prior to
TAVR and prior to CMR.Echocardiography
TTE was performed on a Phillips iE33 (Leiden, The
Netherlands) or General Electric Vivid 7 (Milwaukee,
Wisconsin) as the initial test for the evaluation of PVL.
PVL was classified qualitatively by visual assessment at the
point of care, as well as semi-quantitatively by VARC II cri-
teria post-hoc. Qualitative echocardiography (QE) included
visual estimation of the width and area of the color Dop-
pler jet in the left ventricular outflow tract in the paraster-
nal short and long-axis views and was graded mild (jet
width < 25% of left ventricular outflow tract width), moder-
ate (jet width 25 to 65% of left ventricular outflow tract
width), and severe (jet width >65% of left ventricular
outflow tract width). For semi-quantitative echocardi-
ography (SQE), the VARC II PVL classification scheme
was employed using the circumferential extent of the
regurgitant jet(s) in the parasternal short-axis (the sum
of the PVL jet circumferences divided by the valve cir-
cumference; graded as mild <10%, moderate 10 to 30%,
severe >30%; see Figure 1). Suprasternal notch and sub-
costal views of the descending aorta and parasternal
short and long-axis view of the right ventricular out-
flow tract and main pulmonary artery were consistently
attempted.
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CMR was performed on a Siemens Avanto 1.5 T scan-
ner (Erlangen, Germany) using a 5 element phased array
coil. Velocity-encoded phase-contrast magnetic resonance
(PCMR) imaging was utilized in the ascending aorta for
flow quantification [12]. The scan plane was placed per-
pendicular to the long-axis of the proximal ascending aorta
2-3 mm above the valve stent frame for through-plane flow
measurement in patients with a balloon-expandable pros-
thesis (see Figure 2A) and at a similar position through
the non-ferromagnetic stent frame in patients with a self-
expanding prosthesis. Free-breathing acquisitions were
used preferentially, including patients with irregular heart
rhythms, with breath-hold acquisitions reserved for pa-
tients with respiratory image artifacts due to irregular
breathing. Electrocardiographic triggering was used to
obtain 20 frames per cardiac cycle for patients with a
regular heart rhythm, while free-breathing real time ac-
quisitions with multiple signal averaging was used for
patients with an irregular heart rhythm; the slice thickness
was 6 mm. The VENC was initially set at 200–250 cm/s
with routine VENC optimization.Figure 2 Measurement of paravalvular leak (PVL) regurgitant fraction
of the scan plane is demonstrated for the balloon-expandable prosthesis in
of interest are traced on the magnitude images (anatomical scan; B) and
entire intra-luminal, cross sectional area of flow just above the transcathe
throughout the cardiac cycle (D), with the area under the curve (above b
curve (below baseline) representing reverse flow volume. The aortic regu
by the forward flow volume (mild ≤ 20%, moderate 21-39%, severe ≥40%Cardiovascular magnetic resonance analysis
For the assessment of aortic RF, the cross sectional area
of the aorta was traced throughout the cardiac cycle on
each separate magnitude image to define regions of
interest (see Figure 2B). The forward and reverse flow
volumes were calculated within the corresponding re-
gion of interest on the phase image (see Figure 2C) by
offline analysis using Siemens Argus software (Erlangen,
Germany). Background phase offset correction was done
by using a region of static tissue near the ascending aorta.
Aortic RF was calculated as: reverse aortic flow volume di-
vided by forward aortic flow volume; see Figure 2D. CMR
PVL severity was classified by regurgitant fraction (RF;
mild ≤ 20%, moderate 21 to 39%, severe ≥40%).
PVL classification comparison
The classification of PVL was compared using three mo-
dalities in all patients: QE, SQE, and CMR (used as the
gold standard for this study). By convention, PVL was
classified as 1 (mild), 2 (moderate) and 3 (severe) for
analysis. Inter-method agreement of classification was
analyzed within each patient and for the whole group.(RF) by cardiovascular magnetic resonance (CMR). The positioning
the aortic root 2-3 mm above the valve stent frame (A). The regions
the phase images (flow scan; C). The regions of interest include the
ter valve. The flow through the region of interest is calculated
aseline) representing forward flow volume and the area above the
rgitant fraction was calculated by dividing the reverse flow volume
).
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relative to QE and SQE. PVL severity was considered
downgraded if the CMR classification was ≥1 grade
lower and upgraded if ≥1 grade higher as compared to
each TTE method.
Outcomes
Study outcomes were determined by retrospective chart
review. All patients in this analysis were enrolled in pro-
spective TAVR trials or registries with long-term follow-
up and data collection at our clinic. Follow-up included
detailed interval histories including any hospital admis-
sions or procedures taking place at Emory University
Hospital or outside healthcare facilities. Any patient
deaths not taking place at Emory University Hospital
were reported to clinic study personnel and documented
in the chart, as well. The primary composite outcome
was the combination of all-cause death, heart failure
hospitalization, and intractable heart failure symptoms
necessitating repeat invasive therapy at one-year follow-
up. The secondary composite outcome included the
combined endpoints of all-cause death and heart failure
hospitalization. Intractable heart failure included New
York Heart Association (NYHA) class III and IV symptoms
despite aggressive oral diuretic and/or vasodilator therapy.
Repeat invasive therapy for significant PVL included repeat
balloon valve dilation, transcatheter PVL plug placement,
transcatheter valve-in-valve placement, or surgical valve
replacement. Heart failure hospitalization included any
inpatient admission for congestive symptoms including
worsening dyspnea and peripheral edema during which the
patient was treated with intravenous diuretic and/or
vasodilator therapy.
Statistics
Statistical analysis was performed with SPSS version 20
(Chicago, Illinois) and SAS version 9.3 (Cary, North
Carolina). Descriptive results were expressed as num-
bers and percentages, while continuous variables were
expressed as mean ± standard deviation (unless other-
wise stated). Continuous variables were analyzed by the
independent-samples t-test. Categorical variables were
analyzed by the Fisher’s exact test. PVL classification by
each method was compared within patients by Spearman
rho bivariate correlation and the groups were compared
by the paired-samples Wilcoxon rank-sum test. Baseline
risk was compared across mild, moderate, and severe PVL
by CMR with the Kruskal-Wallis test to evaluate for sig-
nificant differences between the groups. The difference in
event-free survival according to greater than mild PVL
versus mild or less PVL by QE, SQE, and CMR were eval-
uated by Kaplan-Meier survival analysis with Mantel-Cox
log-rank. Inter-observer variability was assessed with
intraclass correlation for continuous variables and Cohen’skappa coefficient for dichotomous classification (sever-
ity greater than mild versus mild or less). Statistical




CMR was performed in 23 post-TAVR patients with
NYHA class III-IV symptoms (median 6 days [interquar-
tile range 2–100 days] post-TAVR and median 2 days
[interquartile range 0–7 days] after index echocardio-
gram). The baseline Society for Thoracic Surgeons Pre-
dicted Risk of Mortality score was not significantly
different among patients with mild, moderate, and se-
vere PVL by CMR (p = 0.26). Baseline patient character-
istics at the time of TAVR are presented in Table 1 and
interval clinical and imaging characteristics at the time
of CMR in Table 2. Patients with significant PVL with
RF > 20% on CMR were more likely to have atrial fibril-
lation at baseline. At the time of CMR, patients with a
RF > 20% had higher serum creatinine, higher serum
brain-natriuretic peptide levels, larger PVL circumferen-
tial extent, and higher prevalence of other valve dysfunc-
tion of at least moderate degree (mitral and tricuspid
regurgitation). Otherwise, there were no significant base-
line differences at the time of TAVR or at the time of
CMR in those with RF > 20% versus RF ≤ 20%.
Paravalvular leak classification by echocardiography and
CMR
All patients had adequate parasternal short-axis images on
echocardiogram for semi-quantitative analysis. Supraster-
nal notch and subcostal views of the descending aorta
were not consistently of diagnostic quality to assess dia-
stolic flow reversal. Parasternal short and long-axis views
of the right ventricular outflow tract and pulmonary artery
were also not consistently of diagnostic quality to perform
quantitative Doppler analysis. PVL classification by QE,
SQE, and CMR is shown in Figure 3. Greater than mild
PVL was present in 52%, 83% and 52% of patients by QE,
SQE, and CMR, respectively. There was a poor correlation
between QE and CMR (Spearman r = 0.26, p = 0.24) and a
moderate correlation between SQE and CMR (Spearman
r = 0.59; p = 0.003). Mean PVL severity was not signifi-
cantly different by QE and CMR, however, SQE overesti-
mated severity compared to CMR (see Figure 4). PVL was
reclassified by CMR in a substantial number of patients
compared with QE and SQE (see Table 3).
Primary composite outcome
At one year (mean 11.5 ± 1.4 months), 48% of the pa-
tients met the primary composite outcome of all-cause
death, heart failure hospitalization, and intractable heart
failure symptoms necessitating repeat invasive therapy
Table 1 Baseline patient characteristics at TAVR*
All (n = 23) RF < 20% (n = 11) RF > 20% (n = 12) P value
Male 16 (70) 6 (55) 10 (83) 0.19
Age (mean ± SD) 83 ± 6 83 ± 7 82 ± 5 0.86
NYHA class (mean ± SD) 3.2 ± 0.7 3.1 ± 0.7 3.3 ± 0.8 0.61
STS-PROM (%; mean ± SD) 6.9 ± 2.4 6.4 ± 2.0 7.4 ± 2.7 0.33
Body mass index (kg/m2) 25 ± 4 25 ± 4 24 ± 4 0.64
Comorbidities
Coronary artery disease 13 (57) 7 (64) 6 (50) 0.68
CABG 7 (30) 2 (18) 5 (42)
PCI 8 (35) 4 (36) 4 (33)
Myocardial infarction 7 (30) 3 (27) 4 (33)
Atrial fibrillation 10 (44) 2 (18) 8 (67) 0.04
Diabetes mellitus 10 (44) 5 (46) 5 (42) 1.00
Hypertension 21 (91) 10 (91) 11 (92) 1.00
Serum creatinine>1.5 mg/dl 8 (35) 2 (18) 6 (50) 0.19
COPD 8 (35) 3 (27) 5 (42) 0.67
Laboratory
Creatinine (mg/dl; median [IQR]) 1.11 (0.90, 1.61) 1.07 (1.00, 1.30) 1.45 (0.86, 1.89) 0.18
BNP (pg/ml; median [IQR]) 545 (226, 1612) 297 (197, 843) 1385 (360, 1806) 0.17
Echocardiography
Ejection fraction (%; mean ± SD) 47 ± 14 45 ± 13 49 ± 15 0.46
Aortic insufficiency* (mean ± SD) 1.1 ± 0.7 1.0 ± 0.7 1.1 ± 0.7 0.90
RVSP (mmHg; mean ± SD) 48 ± 17 43 ± 12 53 ± 19 0.17
RVSP >55 mmHg 7 (30) 2 (18) 5 (42) 0.37
Transfemoral approach 17 (74) 6 (55) 11 (92) 0.07
*All results are presented as n (%) unless otherwise noted.
BNP = brain natriuretic peptide, CABG = coronary artery bypass grafting, COPD = chronic obstructive pulmonary disease, IQR = interquartile range, NYHA = New
York Heart Association, PCI = percutaneous coronary intervention, RVSP = right ventricular systolic pressure, STS-PROM = Society of Thoracic Surgeons predicted risk
of mortality, TAVR = transcatheter aortic valve replacement.
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(9 days for repeat invasive therapy, 97 days for heart fail-
ure admission, and 118 days for all-cause death). Patients
who experienced the primary outcome had significantly
higher serum creatinine levels at the time of CMR (1.9 ±
0.80 mg/dl versus 1.17 ± 0.32 mg/dl, p = 0.008) and higher
EF by CMR (53 ± 10% versus 44 ± 12%, p = 0.048). The
primary outcome occurred in 9%, 71%, and 100% of pa-
tients with mild, moderate, and severe PVL by CMR, re-
spectively. Patients with greater than mild PVL by CMR
were more likely to experience the primary outcome com-
pared to those with mild or less PVL (p = 0.001), while pa-
tients with greater than mild PVL by QE or SQE were not
(p = 1.0 and p = 0.093, respectively). Otherwise, there were
no significant baseline differences in patients with and
without a primary outcome event. Severity of PVL by QE,
SQE, and CMR in those with and without a primary out-
come event is shown in Figure 5. Kaplan-Meier survival
analysis stratified by greater than mild PVL stratified by
QE, SQE, and CMR is shown in Figure 6.Secondary composite outcome
At one year, 35% of patients met the secondary composite
outcome of all-cause death and heart failure hospitaliza-
tion. The average time to heart failure admission was
109 days and average time to death was 150 days. The sec-
ondary outcome occurred in 9%, 57%, and 60% of patients
with mild, moderate, and severe PVL by CMR, respect-
ively. Patients with greater than mild PVL by CMR were
significantly more likely to experience a secondary com-
posite outcome event compared to those with mild or less
PVL (p = 0.027), while patients with greater than mild
PVL by QE or SQE were not (p = 0.19 and p = 0.26, re-
spectively). Otherwise, there were no significant differences
in patients with and without a secondary outcome event.
Kaplan-Meier survival analysis stratified by greater than
mild PVL by QE, SQE, and CMR is shown in Figure 7.
Reproducibility analysis
Inter-observer variability for QE, SQE and CMR was
assessed by 2 independent readers (G.H. and S.L.) in 10
Table 2 Patient characteristics at time of CMR*
All (n = 23) RF < 20% (n = 11) RF > 20% (n = 12) P value
Age (mean ± SD) 83 ± 6 83 ± 7 83 ± 5 0.82
NYHA class (mean ± SD) 3.5 ± 0.8 3.4 ± 0.9 3.7 ± 0.7 0.37
ΔNYHA class since TAVR (median[IQR]) 1 (0, 1) 1 (−1, 1) 0 (0, 1) 0.77
STS-PROM (%; mean ± SD) 7.8 ± 4.6 6.3 ± 2.3 9.0 ± 5.7 0.16
ΔSTS-PROM since TAVR (%; median[IQR]) 0 (−0.5, 1.7) 0 (−1.1, 0) 0.8 (−0.4, 3.0) 0.15
Laboratory
Creatinine (mg/dl; median[IQR]) 1.29 (1.00, 1.84) 1.11 (1.00, 1.37) 1.61 (1.06, 2.63) 0.011
ΔCreatinine since TAVR (mg/dl; median[IQR]) 0.1 (−0.06, 0.39) 0.03 (−0.08, 0.19) 0.36 (0.10, 0.55) 0.13
BNP (pg/ml; median[IQR])) 496 (252, 1335) 432 (235, 546) 1038 (339, 1948) 0.05
ΔBNP since TAVR (pg/ml; median[IQR]) 0 (−419, 199) 0 (−411, 85) 68 (−441, 240) 0.73
Echocardiography
Circumferential extent (%; mean ± SD) 34.2 ± 18.4 23.3 ± 18.2 44.3 ± 11.9 0.003
CMR
Ejection fraction (%; mean ± SD) 48 ± 12 47 ± 10 49 ± 14 0.78
Other valve disease greater than mild† 14 (61) 4 (36) 10 (83) 0.04
*All results are presented as n (%) unless otherwise noted.
†Includes mitral and tricuspid regurgitation.
BNP = brain natriuretic peptide, CMR = cardiovascular magnetic resonance, IQR = interquartile range, NYHA = New York Heart Association, PVL = paravalvular
leak, RF = regurgitant fraction, STS-PROM = Society of Thoracic Surgeons predicted risk of mortality, TAVR = transcatheter aortic valve replacement,
TTE = transthoracic echocardiography.
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intraclass correlation coefficient for PVL severity by vis-
ual grading was 0.61 (p = 0.022), with excellent agreement
between readers for PVL classification (Cohen’s kappa co-
efficient 1.0, p = 0.002). For SQE, the intraclass correlation
coefficient for PVL circumferential extent by the VARC II
method was 0.58 (p = 0.030), with good agreement between
readers for PVL classification (Cohen’s kappa coefficient
0.60, p = 0.016). For CMR, the intraclass correlation coeffi-
cient for PVL regurgitant fraction was 0.93 (p < 0.0001)
with excellent agreement between readers for PVL classifi-
cation (Cohen’s kappa coefficient 0.82, p < 0.0001).
Discussion
We present an early experience demonstrating the added
value of CMR for diagnostic classification and risk strati-
fication in symptomatic patients with post-TAVR PVL.
PVL classification by PCMR flow quantification was re-
producible and provided prognostic value superior to both
qualitative and semi-quantitative echocardiography, sug-
gesting that more widespread use of CMR derived PVL
quantification may be warranted in symptomatic post-
TAVR patients. Flow quantification by PCMR is a well-
established method for evaluating proximal aortic forward
and reverse volumes [7,8]. Aortic regurgitation quantifica-
tion is more reproducible by CMR compared to echocar-
diography for native valve disease [13,14], however, it is
noteworthy that quantitative RF values of aortic regurgita-
tion severity obtained by PCMR are systematically lower
than those obtained by echocardiography [15,16]. CMRderived quantitative findings have also shown prognostic
value in native aortic regurgitation patients [17]. We
present the first study evaluating the prognostic value of
CMR derived PVL quantification in post-TAVR patients,
in addition to diagnostic reclassification of PVL by CMR
relative to various echocardiographic techniques.
CMR has demonstrated feasibility for the quantification
of post-TAVR PVL [9-11]. In contrast to native aortic
valve regurgitation, post-TAVR PVL is underestimated by
QE compared to CMR [10,18,19]. Sherif et al. initially
showed that QE underestimated the degree of PVL by ≥1
grade in 7 of 16 (44%) patients compared to CMR [10].
Recently, a multiparametric TTE approach was found to
underestimate the degree of PVL by ≥1 grade relative to
CMR to a varying extent: 15 of 65 (23%) patients in Orwat
et al. [18] and 26 of 42 (62%) patients in Ribiero et al. [19].
These findings are consistent with our study, in which QE
identified no cases of severe PVL and PVL severity was
upgraded by CMR by ≥1 grade in nearly one-third of pa-
tients. A notable difference between our study and those
above is that they utilized routine CMR screening in post-
TAVR patients regardless of symptoms, while our study
evaluated CMR as a strategy to clarify post-TAVR symp-
toms. Importantly, we demonstrated limited prognostic
power of QE while CMR was a strong predictor of adverse
events, which highlights the clinical importance of the dis-
crepancies between PVL grading with these modalities.
It is generally accepted that greater than mild PVL by
echocardiography is associated with worse patient out-
comes post-TAVR [3,4]. However, both transthoracic
Figure 3 Comparison of paravalvular leak (PVL) classification
by qualitative echocardiography (QE), semi-quantitative
echocardiography (SQE), and cardiovascular magnetic resonance
(CMR). QE classification included the estimated width of the color
Doppler jet in the left ventricular outflow tract: mild (jet width < 25%
of left ventricular outflow tract width), moderate (jet width 25 to 65%
of left ventricular outflow tract width), and severe (jet width >65% of
left ventricular outflow tract width). SQE included the circumferential
extent as the sum of the paravalvular leak jet circumference(s) divided
by the valve circumference: mild (<10%), moderate (10-30%), and
severe (>30%). CMR classification included the aortic regurgitant
fraction as calculated by dividing the reverse flow volume by the
forward flow volume: mild (≤20%), moderate (21-39%), and
severe (≥40%).
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cant limitations for the characterization and quantifica-
tion of post-TAVR PVL. These limitations are related to
two-dimensional anatomic views, angle dependence of
Doppler assessment, multiple eccentric jets, and signal at-
tenuation due to native calcification and implanted pros-
thetic material. Any combination of these factors can
result in PVL underestimation. Such underestimation of
post-TAVR PVL by QE may have led to previous findings
implying that even mild post-TAVR PVL is associated with
worse outcomes [1]. In our study, PVL severity by QE did
not predict patient outcomes, further highlighting the lim-
itations of QE in risk stratifying post-TAVR PVL. The as-
sessment of PVL by PCMR overcomes the limitations of
anatomic views and visual assessment to provide a truly
quantitative evaluation of retrograde diastolic flow in the
proximal aorta. Importantly, PCMR is technically feasible
for PVL assessment in the balloon-expandable and self-Figure 4 Comparison of mean paravalvular leak (PVL) grade
by qualitative echocardiography (QE), semi-quantitative
echocardiography (SQE), and cardiovascular magnetic resonance
(CMR). PVL classification: mild = 1, moderate = 2, severe = 3. Error bars = 2
standard errors of the mean. P values are for paired-samples t-test.
Table 3 Number of patients in which the PVL grade was
reclassified after performing CMR
All n = 23 (%)
Qualitative echocardiography reclassification 11 (48)
Upgrade 7 (31)
Downgrade 4 (17)
Semi-quantitative echocardiography reclassification 13 (57)
Upgrade 0 (0)
Downgrade 13 (57)
CMR = cardiovascular magnetic resonance, PVL paravalvular leak, RF = regurgitant
fraction, TTE = transthoracic echocardiography.
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States [10].
In an attempt to improve echocardiographic analysis,
SQE has been performed in addition to QE. However,
there is concern that PVL classification by SQE circum-
ferential extent per VARC II criteria overestimates post-
TAVR PVL severity as compared to quantitative Doppler
[6,19,20] and CMR quantification [21]. Although tech-
nical limitations precluded routine quantitative Doppler
in our series of symptomatic patients, we also found over-
estimation of PVL severity by SQE compared to CMR,
with greater than 80% of patients classified as having
greater than mild PVL by SQE compared to 48% by CMR.
These findings are in concordance with those of Ribiero
et al. [19], who found that 38% of their asymptomatic
post-TAVR patients had greater than mild PVL by SQE
compared to 24% by CMR. Our study also demonstrated
inferior prognostic power of SQE compared to CMR.
Our study demonstrates that greater than mild post-
TAVR PVL by CMR is associated with a worse prognosis
in a symptomatic population. This finding is supported
by data from Merten et al. demonstrating that patients
with no or mild post-TAVR PVL by CMR undergo bene-
ficial LV structural remodeling, while those with greater
than mild PVL do not [9]. A left ventricle that has chron-
ically remodeled to facilitate pressure overload from aortic
stenosis is expected to poorly tolerate moderate or severe
regurgitation. Symptoms related to post-TAVR PVL mightTable 4 Follow-up Primary Composite Outcomes
All n = 23
(%)
RF ≤ 20%
n = 11 (%)
RF > 20%
n = 12 (%)
P value*




8 (35) 0 (0) 8 (67)
Heart failure
hospitalization
4 (17) 0 (0) 4 (33)
All-cause death 5 (22) 1 (9) 4 (33)
*For Fisher’s exact test.
RF = cardiovascular magnetic resonance derived regurgitant fraction.
Figure 5 Comparison of paravalvular leak (PVL) severity in
patients with different primary composite outcomes by
imaging method. (A) Qualitative echocardiography (QE): 1 = mild,
2 =moderate, 3 = severe. (B) Semi-quantitative echocardiography
(SQE) circumferential extent: mild (<10%), moderate (10-30%), and
severe (>30%). (C) Cardiovascular magnetic resonance (CMR) regurgitant
fraction: mild (≤20%), moderate (21-39%), and severe (≥40%).
Primary composite outcome = repeat invasive therapy, heart failure
hospitalization, and all-cause death. P values are for independent
samples t-test.
Figure 6 Primary composite outcome Kaplan-Meier survival
analysis for patients with greater than mild paravalvular leak
(PVL) by imaging method. QE = qualitative echocardiography,
SQE = semi-quantitative echocardiography, CMR = cardiovascular
magnetic resonance. CE = circumferential extent. Primary composite
outcome = repeat invasive therapy, heart failure hospitalization, and
all-cause death.
Figure 7 Secondary composite outcome Kaplan-Meier survival
analysis for patients with greater than mild paravalvular leak
(PVL) by imaging method. QE = qualitative echocardiography,
SQE = semi-quantitative echocardiography, CMR = cardiovascular
magnetic resonance. CE = circumferential extent. Secondary composite
outcome = heart failure hospitalization and all-cause death.
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http://jcmr-online.com/content/16/1/93be difficult to differentiate from those related to systolic or
diastolic heart failure and we believe CMR adds incremental
value in this situation [22]. Our initial findings utilizing
highly reproducible CMR quantification support further
prospective validation of CMR for the evaluation and
prognostication of post-TAVR PVL in a larger popula-
tion of TAVR patients.Limitations
The primary limitations of our study are the small number
of patients from a single institution and retrospective col-
lection of data. Small sample size may contribute to lim-
ited power to draw conclusive results, however this issue
may be mitigated by the high event rate (48%) for the pri-
mary composite outcome in this highly symptomatic co-
hort. The inclusion of symptomatic post-TAVR patients
from our single institution also limits external validity, so
generalization beyond our sample must be done with
caution. Retrospective analysis may not account for
unidentified confounders associated with poor out-
comes post-TAVR, however, all patients were taking
part in parallel prospective TAVR trials or registries in
which meticulous follow-up and data collection were
ensured.
Our primary composite outcome included repeat inva-
sive therapy for refractory heart failure symptoms due to
PVL, which could be driven by CMR findings and thus
cause post-test bias. The secondary composite outcome,
which did not include repeat invasive therapy, was sig-
nificant for patients with >20% RF by CMR. Many of
our patients had difficult or suboptimal echocardiography.
Semi-quantitative assessment using descending aortic flow
reversal and quantitative assessment using right ventricu-
lar outflow tract or pulmonary artery Doppler were not
routinely performed. This deficit likely reflects a modality
specific shortcoming, as even experienced echocardiog-
raphy centers report a substantial rate of technically diffi-
cult routine studies [23].Conclusions
CMR stratifies post-TAVR PVL severity and should be
considered early in the evaluation of symptomatic post-
TAVR patients. CMR is highly reproducible and com-
monly reclassifies PVL grade compared with qualitative
and semi-quantitative TTE. Patients with greater than
mild PVL by CMR (RF > 20%) had a higher incidence of
the primary composite outcome of all-cause death, heart
failure hospitalization and intractable heart failure symptoms
necessitating repeat invasive therapy.Competing interests
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